Year: 2021

VANCOUVER, British Columbia, Nov. 15, 2021 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) (“SHARC Energy” or the “Company”) announces it has filed its financial results for the third quarter and the nine months ended September 30, 2021. All figures are in Canadian Dollars unless otherwise stated and in accordance with IFRS. Third Quarter and Year to date Highlights:Revenue for the three months ended September 30, 2021 (“Q3 2021”) was $1.42M, representing an increase of 234% or 0.99M from the three months ended September 30, 2020 (“Q3 2020”). This is the largest revenue quarter in the Company’s history.Revenue for the nine months ended September 30, 2021 (“YTD 2021”) was $1.72M, representing an increase of 190% or $1.13M from the nine months ended September 30, 2020 (“YTD...

Board approves exploration of a Company-sponsored belapectin oncology program complementing our ongoing NASH cirrhosis program Leading oncology experts engaged to consult on strategic planning and operational direction in the development of belapectin in cancer immunotherapy Management team strengthened with the appointment of Hugh Huang, Ph.D., as Vice President, CMC Pharmaceutical Development NORCROSS, Ga., Nov. 15, 2021 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended September 30, 2021. These results are included in the Company’s Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel...

Management to host conference call today, November 15 at 11:30AM Eastern Time MELVILLE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) — Data Storage Corporation (Nasdaq: DTST) (“DSC” and the “Company”), a provider of diverse business continuity, disaster recovery protection, IBM Power infrastructure-as-a-service, cyber-security based and data analytics solutions, today provided a business update and reported its financial results for the third quarter ended September 30, 2021. Chuck Piluso, CEO of Data Storage Corporation, commented, “I’m pleased to report revenue for the third quarter increased 42% compared to the same period last year, and we continue to generate positive net income, while investing in the future growth of the Company. We saw a meaningful increase in sales across Infrastructure & Disaster Recovery/Cloud Services,...

Acumen’s investigational product candidate, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical trials Enrolled first patients in INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease Closed initial public offering in July 2021, with aggregate net proceeds of $168.6 millionCHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 15, 2021 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today reported financial results for the quarter ended September 30, 2021 and provided...

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced our financial results for the quarter ended September 30, 2021, and recent events. “We continue to make progress with clinical trial sites to participate in our global Phase 2b/3 trial of AV-101 in PAH and expect to initiate enrollment this year in the Phase 2b portion of the trial,” said Timothy Noyes, chief executive officer of Aerovate. “We are also pleased with investor support for our IPO, which we believe provides sufficient capital to fund Aerovate into the second half of 2025.” Recent Events Raised $126.9 Million in Net Proceeds from IPO. On July 2, 2021, we closed...

Launched Trudhesa™ (dihydroergotamine mesylate) Nasal Spray (0.725 mg per spray) for the Acute Treatment of Migraine with and without Aura in Adults Mobilized 60-Person Salesforce with a Targeted Focus on High-Prescribing Neurologists, Headache Specialists and Primary Care Physicians Increased Cash Position and Extended Runway into 2023 with Follow-on Equity Offering of 3.45 Million Shares Valued at $51.8 Million Company Plans to Initiate Phase 2a Proof-of-Concept Trial Evaluating INP105 in Agitation and Aggression in Autism in Late Q4 2021 Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, Nov. 15, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial...

– Initiation of a pivotal Phase 3 trial evaluating the efficacy and safety of brilaroxazine for the treatment of schizophrenia expected by year-end – – Additional Phase 3 trial evaluating the long-term safety of brilaroxazine in adult patients with schizophrenia expected to begin by year-end – – $33.5 Million in Cash as of September 30, 2021 – CUPERTINO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today reported financial results for the third quarter of 2021 and summarized recent business highlights. “We look forward...

Fourth consecutive quarter of positive gross margin, second consecutive quarter of positive manufacturing operating income Company reiterates delivery outlook for fiscal year 2021 CHICAGO, Nov. 15, 2021 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) today reported results for the third quarter ended September 30, 2021. Business Highlights                Third quarter revenue was $58.3 million, up 131% year-over-year, on deliveries of 505 railcars Gross margin was $1.5 million, positive for the fourth consecutive quarter, despite difficult launch of new model Manufacturing operating income was $0.2 million, the second consecutive positive result Third quarter net income was $0.7 million, or $0.03 per share Adjusted EBITDA loss was ($3.5) million Quarter-end backlog totaled 1,895 railcars with an aggregate value of...